PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $33.53 Average

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Reduce” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The average […]

Related Keywords

United States , Canada , China , Allan Steven Jacobson , Hexagon Capital Partners , Wells Fargo Company , Cantor Fitzgerald , Lazard Asset Management , Securities Exchange Commission , Morgan Stanley , Nisa Investment Advisors , China Universal Asset Management Co , Nasdaq , Therapeutics Company Profile , Royal Bank , Ptc Therapeutics Inc , Therapeutics Inc , Get Free Report , Stock Down , Director Allan Steven Jacobson , Exchange Commission , Marie Utter , Capital Partners , Universal Asset Management , Asset Management , Investment Advisors , Get Free , Ptc Therapeutics , Nasdaq Ptct , Ptct , Medical , Ratings , Consensus ,